Hansa Biopharma — December 2022
-
Hansa avser att använda nettolikviden från den riktade nyemissionen för att påbörja förberedelser för en potentiell lansering av imlifidase i USA för njurtransplantation, stärka pågående produktutvecklingsaktiviteter och utvidga bolagets forsknings- och utvecklingspipeline.
-
Ret imponerende, at den rettede emi gennemføres stort set til dagskursen.
-
Ja, det er MEGET positivt
Meget bedre end kraftig udvanding til eksisterende aktionærer,
til en eller anden lav kurs. -
Braidwell har også haft en heldig (22. november 22) hånd mht. Compass Therapeutics:
Compass Therapeutics Announces $80 Million Private Placement
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing...
GlobeNewswire News Room (www.globenewswire.com)
... som er oppe med +116% de seneste 6 måneder.
-
Hansa Biopharma: Adding growth capital ahead of the US launch
-
"Hansa has done a directed share issue adding SEK 420m in growth capital mainly supporting the US launch of Idifirix and to progress with an already extensive pipeline of opportunities ahead. A sizeable directed share issue directed to international institutions at a minimal rebate can be considered as a sign of strength in these market conditions."
Redeye er hurtigt ude med en lynanalyse. Redeye gør det altså godt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind